drugset / Trial / NCT07378761
Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis
RandomizedParallel-groupOpen-labelTreatment
Summary
The clinical trial aims to compare the effectiveness of ursodeoxycholic acid (UDCA) to corticosteroids in treating cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs) over a 21-day period. The trial presents a detailed scientific justification for comparing UDCA to corticosteroids, describing the treatment and detailing the follow-up procedures. It hypothesizes that UDCA could be superior to corticosteroids for treating ICI-related cholestatic hepatitis, based on its established use in primary biliary cholangitis and a favorable tolerance profile compared to corticosteroids.
Timeline
- Start
- 2026-12
- Primary completion
- 2028-09
- Completion
- 2029-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ursodeoxycholic Acid | Small molecule | 13 mg/kg | Oral |
| Subject | Ursodeoxycholic Acid | Small molecule | 15 mg/kg | Oral |